A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of AG-014699 in diabetic patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Rucaparib

Criteria

Inclusion Criteria:

• diabetic patients, either man or woman, with diabetic retinopathy, at least 18 years of age

Exclusion Criteria:

• patients treated with laser therapy within the last 90 days

• patients with likelyhood to require cataract surgery within 3 months

• Uncontrolled diabetes